Form 4: Inovio Pharmaceuticals CFO Peter Kies Reports Stock Transactions

CFO of Inovio Pharmaceuticals, Peter Kies, reports transactions involving common stock and restricted stock units, including vesting, tax withholding, and option grants.

Summary

• Peter Kies, CFO of Inovio Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 26, 2024, restricted stock units vested, resulting in the acquisition of 1,878 and 3,997 shares of common stock.
• Shares were withheld by the issuer to cover tax obligations related to the vesting of these restricted stock units, totaling 1,108 and 2,358 shares respectively.
• These transactions occurred at a price of $8.16 per share.
• Kies also acquired 18,750 common stock options on February 28, 2024, exercisable at $8.46, and 15,029 restricted stock units.
• The reported transactions reflect a 1-for-12 reverse stock split that Inovio Pharmaceuticals effected on January 24, 2024.
• Kies directly owns 22,158 shares of common stock and indirectly owns 375 shares through a spouse.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.

Positives

• The granting of stock options and restricted stock units to the CFO could align his interests with those of the shareholders.

Industry Context

Form 4 filings are standard practice for reporting insider transactions and are publicly available to ensure transparency in the market.

Stakeholder Impact

• Shareholders can use this information to understand the actions of company insiders.

Key Dates